NEUROCRINE BIOSCIENCES INC (NBIX) Free cash flow 2016–2025
NEUROCRINE BIOSCIENCES INC (NBIX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$748.7MFY2025 · since FY2016: -$110.3M → $748.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $748.7M | +34.4% |
| FY2024 | $557.2M | +54.1% |
| FY2023 | $361.6M | +12.0% |
| FY2022 | $322.9M | +38.5% |
| FY2021 | $233.1M | +7.1% |
| FY2020 | $217.6M | +64.5% |
| FY2019 | $132.3M | +72.7% |
| FY2018 | $76.6M | +175.6% |
| FY2017 | -$101.3M | +8.2% |
| FY2016 | -$110.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NBIX financial trends
NBIX RevenueNBIX Net incomeNBIX Net marginNBIX Gross profitNBIX Gross marginNBIX Operating incomeNBIX Operating marginNBIX Operating cash flowNBIX Capital expendituresNBIX Return on equityNBIX Stock buybacksNBIX Dividends paidNBIX Total assetsNBIX Total liabilitiesNBIX Shareholders’ equityNBIX overview →